PI Form 4: Chris Diorio Disposes 10,000 Shares in August 2025
Rhea-AI Filing Summary
Insider Form 4 — Impinj, Inc. (PI) Dr. Chris Diorio, CEO and Director, reported preplanned sales under a Rule 10b5-1 trading plan effective May 28, 2025. The filing discloses a total of 10,000 shares sold across transactions on August 28–29, 2025, in multiple tranches with reported weighted-average prices by tranche ranging approximately from $185.93 to $190.79. After these disposals Dr. Diorio directly beneficially owned 356,109 shares and indirectly owned 199,362 shares through DFT L.L.C. The filing includes explanations that sales were executed pursuant to the 10b5-1 plan and provides price ranges for the individual tranches.
Positive
- None.
Negative
- CEO sold 10,000 shares in August 2025, reducing direct holdings to 356,109 shares.
- Sales were material in aggregate (10,000 shares) and occurred over two days, which some investors may view as notable.
Insights
TL;DR: CEO sold 10,000 shares under a 10b5-1 plan, indicating preplanned dispositions rather than ad-hoc selling.
The sales are explicitly described as executed pursuant to a Rule 10b5-1 trading plan effective May 28, 2025. Use of a pre-established plan generally reduces the likelihood that these transactions reflect contemporaneous, undisclosed company information. The filing discloses tranche-level weighted-average prices and cumulative quantities, which increases transparency. From a governance perspective, documentation of the 10b5-1 plan and clear tranche reporting align with good disclosure practice.
TL;DR: CEO sales totaled 10,000 shares at prices ~ $185.34–$190.93, modest in scale relative to typical institutional holdings.
The filing details nine disposals over two days with weighted-average prices reported by tranche and explicit ranges for individual execution prices. The director remains a substantial shareholder directly (356,109 shares) and indirectly (199,362 shares), so these sales represent a reduction but not a full exit. Because transactions were under a 10b5-1 plan, immediate market-impact interpretation is limited; the disclosure allows investors to verify quantities and price bands if desired.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 2,000 | $188.3865 | $377K |
| Sale | Common Stock | 2,800 | $189.3862 | $530K |
| Sale | Common Stock | 200 | $190.28 | $38K |
| Sale | Common Stock | 1,112 | $185.9255 | $207K |
| Sale | Common Stock | 784 | $186.7989 | $146K |
| Sale | Common Stock | 1,749 | $188.1404 | $329K |
| Sale | Common Stock | 960 | $189.0634 | $182K |
| Sale | Common Stock | 325 | $190.3271 | $62K |
| Sale | Common Stock | 70 | $190.7886 | $13K |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $185.34.00 to $186.32, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $186.43 to $187.305, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $187.5801 to $188.57 inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $188.585 to $189.335, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $189.70 to $190.675, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $190.75 to $190.93, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $188.00.00 to $188.99, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $189.10 to $189.74, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
